UBS Group
DNTH icon

UBS Group’s Dianthus Therapeutics DNTH Stock Holding History

UBS Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Buy
1,140,260
+358,978
+46% +$31.4M 0.01% 1051
2026
Q1 		$65.6M Buy
781,282
+174,662
+29% +$10.1M 0.01% 1369
2025
Q4 		$25M Buy
606,620
+469,547
+343% +$18.2M ﹤0.01% 2366
2025
Q3 		$5.39M Buy
137,073
+5,592
+4% +$143K ﹤0.01% 3959
2025
Q2 		$2.45M Buy
131,481
+84,052
+177% +$1.58M ﹤0.01% 4603
2025
Q1 		$860K Sell
47,429
-6,432
-12% -$142K ﹤0.01% 5413
2024
Q4 		$1.17M Buy
53,861
+25,433
+89% +$654K ﹤0.01% 5184
2024
Q3 		$778K Buy
28,428
+20,019
+238% +$558K ﹤0.01% 4874
2024
Q2 		$218K Sell
8,409
-6,096
-42% -$147K ﹤0.01% 5606
2024
Q1 		$435K Buy
14,505
+14,125
+3,717% +$307K ﹤0.01% 5307
2023
Q4 		$3.95K Buy
380
+61
+19% +$674 ﹤0.01% 7920
2023
Q3 		$4.36K Sell
319
-380
-54% -$4.79K ﹤0.01% 7447
2023
Q2 		$8.47K Buy
699
+524
+299% +$5.96K ﹤0.01% 7236
2023
Q1 		$2.22K Buy
+175
New +$1.94K ﹤0.01% 8548
2022
Q4 		– Sell
-517
Closed -$12K – 10795
2022
Q3 		$12K Buy
+517
New +$14.2K ﹤0.01% 8155
2022
Q1 		– Sell
-451
Closed -$32K – 10373
2021
Q4 		$32K Buy
451
+449
+22,450% +$45.1K ﹤0.01% 7322
2021
Q3 		$0 Sell
2
-8
-80% -$932 ﹤0.01% 9637
2021
Q2 		$2K Sell
10
-77
-89% -$14.1K ﹤0.01% 8936
2021
Q1 		$17K Sell
87
-178
-67% -$30K ﹤0.01% 7510
2020
Q4 		$33K Buy
+265
New +$30K ﹤0.01% 6552
2019
Q4 		– Sell
-562
Closed -$92K – 8153
2019
Q3 		$92K Buy
562
+481
+594% +$91.4K ﹤0.01% 5810
2019
Q2 		$19K Sell
81
-32
-28% -$7.91K ﹤0.01% 6639
2019
Q1 		$30K Buy
+113
New +$19.5K ﹤0.01% 5937
2018
Q4 		– Sell
-99
Closed -$19K – 8080
2018
Q3 		$19K Buy
99
+29
+41% +$6.1K ﹤0.01% 6817
2018
Q2 		$15K Buy
+70
New +$15.8K ﹤0.01% 6884

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

UBS Group's DNTH Position: Q2 2026 in Review

UBS Group increased its Dianthus Therapeutics (DNTH) stake by 46% in Q2 2026, buying an estimated $31.4M and bringing the position to 1,140,260 shares worth $111M. The position accounts for 0.01% of the portfolio, ranked #1051.

UBS Group first reported a position in DNTH in Q2 2018 and has held it in 25 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • UBS Group held 1,140,260 shares of Dianthus Therapeutics worth $111M as of Q2 2026.
  • UBS Group bought 358,978 Dianthus Therapeutics shares in Q2 2026, an estimated $31.4M.
  • Dianthus Therapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1051 holding.
  • UBS Group first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.